SeaStar Medical (ICU) Strengthens Board of Directors

SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) announces that three new members have joined its Board of Directors. Two new directors, Jennifer A. Baird and Bernadette N. Vincent, were elected at the Company’s 2024 Annual Meeting of Stockholders held on June 4, and John Neuman was appointed to the Board on June 5. Former directors Bruce Rodgers and Richard Russell did not stand for reelection at the 2024 Annual Meeting, and Andres Lobo announced his retirement from Dow Chemical, resulting in his departure from the SeaStar Medical Board.

“We are delighted to add three outstanding professionals in Jennifer, Bernadette and John to our Board,” said Rick Barnett, SeaStar Medical’s Chairman. “Our new Directors bring significant leadership, financial and formidable industry experience that will be highly valuable as SeaStar Medical continues its transition to a commercial-stage company. We look forward to their contributions. On behalf of the Board, I’d like to express our appreciation for the services provided by Andres, Bruce and Richard.”

Ms. Baird serves as the Executive Chair of Culturewell, Co., an organization that delivers actionable insight for healthcare infection prevention through environmental sampling testing and germ risk assessments. She previously was CEO and Director of the medical device software company Fifth Eye Inc. and CEO and Director of the renewable energy technology company Accio Energy, Inc. Prior to that, Ms. Baird co-founded and served as CEO and Director at the healthcare-based companies Accuri Cytometers, Inc. (acquired by Becton Dickinson) and Sonetics Ultrasound, Inc. She serves as a Director for the non-profit Hope Clinic and advisor for the Michigan Founders Fund. Ms. Baird holds a BA in organizational psychology/leadership from the University of Michigan and an MBA from the Kellogg Graduate School of Management at Northwestern University.

Ms. Vincent most recently held executive roles including President, Chief Operating Officer and Chief Field Operations Officer and was a Director at Satellite Healthcare Inc., a national non-profit kidney care company. She served on the Quality, Safety & Patient Experience and the Government & Compensation Executive & Strategy committees. Prior to that, Ms. Vincent was Chief Operating Officer for Mednax, Inc., a provider of multi-specialty physician and health system services and held various leadership positions with Fresenius Medical Care North America, including Group Vice President and Vice President of Operations. Ms. Vincent is a Director for the National Kidney Foundation, California & Pacific Northwest Chapter and was Founder-Board member for the Laureate Academy Charter School. She holds a BS in nursing from Dillard University and an MBA from Pepperdine University.

Mr. Neuman retired from The Dow Chemical Company in 2023 following 30 years of service, most recently as Vice President of Global Financial Accounting. In this position, he directed a team of approximately 350 professionals with responsibilities for financial accounting and reporting for a global network of more than 400 legal entities, including SEC filings. His tenure at Dow included finance integration and reporting responsibilities for several transactions, including the Rohm & Haas and Dow Corning acquisitions, and the Dow/DuPont merger. Prior to joining Dow, Mr. Neuman was an audit manager for Deloitte & Touche LLP. He holds a degree in accounting from Michigan State University, is a member of the Michigan State University External Advisory Board for the Department of Accounting and Information Systems and is a Certified Public Accountant (inactive).

You May Also Be Interested In

• Samsung Biologics launches CHF 1.46B tender offer for PolyPeptide
• DBV Technologies refreshes ATM program with $150M ADS offering
• Csquare prices IPO at $21 per share, raising $1.01 billion